RT Journal Article
SR Electronic
T1 Urine extracellular vesicles capture kidney transcriptome and hyperglycemia linked mRNA signatures for type 1 diabetic kidney disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.11.21264829
DO 10.1101/2021.10.11.21264829
A1 Dwivedi, Om Prakash
A1 Barreiro, Karina
A1 Käräjämäki, Annemari
A1 Valo, Erkka
A1 Prasad, Rashmi B
A1 Holthöfer, Harry
A1 Groop, Per-Henrik
A1 Tuomi, Tiinamaija
A1 Forsblom, Carol
A1 Groop, Leif
A1 Puhka, Maija
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264829.abstract
AB Diabetic kidney disease (DKD) is a severe complication of type 1 diabetes (T1D), which lacks non-invasive early biomarkers. Although less explored, mRNAs in urinary extracellular vesicles (uEV) could reflect changes in the kidney transcriptome during DKD development. We performed genome-wide mRNA sequencing of >100 uEV samples from two T1D cohorts with 24-hour and overnight urine collections. Our uEV pipeline allowed reproducible detection of >10,000 mRNAs bearing overall similarity to kidney transcriptome. uEV from T1D DKD groups showed significant upregulation of 13 genes, prevalently expressed by proximal tubular cells within the kidney. Strikingly, six genes involved in cellular stress responses including protection against oxidative stress (GPX3, NOX4, MSRB, MSRA, HRSP12 and CRYAB) correlated with hyperglycemia and long-term changes in kidney function independent of albuminuria status. The study identified genes associated with glycemic stress in T1D DKD and confirmed the utility of uEV in capturing pathological gene expression signatures from kidney.Competing Interest StatementL.G. has received research funding from Pfizer Inc, Regeneron Pharmaceuticals, Eli Lilly and Astra Zeneca. P-H.G. has received research grants from Eli Lilly and Roche; is an advisory board member for AbbVie, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Jansen, MSD, Novartis, NovoNordisk and Sanofi; and has received lecture fees from Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk and Sanofi. The funding sources were not involved in the design or conduct of the study.Funding StatementThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974 (BEAt-DKD). This Joint Undertaking receives support from the European Union Horizon 2020 research and innovation programme and EFPIA with JDRF. The Direva Study (A.K.) has been supported by the Vasa Hospital District, State Research Funding via the Turku University Hospital, Vasa Central Hospital, Jakobstadsnejdens Heart Foundation, the Medical Foundation of Vaasa and the Finnish Medical Foundation. This substudy has also been financially supported (LG, TT) by grants from Folkhälsan Research Foundation, the Sigrid Juselius Foundation, the Academy of Finland (grants no. 263401, 267882, 312063, 336822 to LG: 312072,336826 to TT: 317599 to OPD), University of Helsinki, Ollqvist Foundation, and the Health Care Center in Vasa. The FinnDiane study was supported by grants from Folkhälsan Research Foundation, Wilhelm and Else Stockmann Foundation, Liv och Hälsa Society, Helsinki University Central Hospital Research Funds (EVO), Novo Nordisk Foundation (NNFOC0013659), and Academy of Finland (299200 and 316664).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study protocol for this substudy of the FinnDiane and DIREVA studies was approved by the Ethics Committee of the Turku University Hospital. The study protocol of the FinnDiane Study has also been approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District (FinnDiane 163/E5/04, 199/E5/05, 491/E5/2006, 238/13/03/00/15), and that of DIREVA, by the Ethical Committees of the Vaasa Central Hospital (6/2007) and Turku University Hospital (48/1801/2014, 116/1805/2016). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors